- Home
- RMCO vs ALGS Comparison
RMCO vs ALGS Comparison
Compare RMCO & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCO | ALGS |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 49.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RMCO | ALGS |
|---|---|---|
| Price | $3.97 | $7.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $46.67 |
| AVG Volume (30 Days) | 23.6K | ★ 57.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,611,000.00 |
| Revenue This Year | $531.90 | N/A |
| Revenue Next Year | $200.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $3.76 |
| 52 Week High | $5.00 | $18.99 |
Technical Indicators
Market Signals| Indicator | RMCO | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 43.11 |
| Support Level | $3.81 | $6.23 |
| Resistance Level | $4.12 | $7.71 |
| Average True Range (ATR) | 0.23 | 0.69 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 46.59 | 41.20 |
Price Performance
Historical ComparisonAbout RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.